- Home
- GNPX vs SNTG Comparison
GNPX vs SNTG Comparison
Compare GNPX & SNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNPX | SNTG |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNPX | SNTG |
|---|---|---|
| Price | $2.32 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 22.3K |
| Earning Date | 11-14-2025 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $107,507.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.71 | $1.43 |
| 52 Week High | $55.00 | $12.70 |
Technical Indicators
Market Signals| Indicator | GNPX | SNTG |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 55.56 |
| Support Level | $2.63 | $2.24 |
| Resistance Level | $3.04 | $2.48 |
| Average True Range (ATR) | 0.43 | 0.16 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 31.28 | 70.34 |
Price Performance
Historical ComparisonAbout GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.